Where were these people when the 1st Heart Transplants were being done? Were they demanding a placebo surgery then? Maybe some patients to get a real heart and some to get surgery with no transplant but let them "think" they had a transplant...sounds ridiculous doesn't it..
Chaim Lebovitz of bcli stated it as well. Pretty scary. This is why A fukstein and the rest of the dbags who try to give their opinions when they have no qualifications on the matter should not be listened to.
Long before the FDA existed, scientists used several approaches to discovering truth.
At least two major designs for experiments do exist.
Group designs are most well known, in which two groups of subjects get treatment or placebo.
Single case designs are where one subject gets a series of interventions: first a non-treatment baseline, then treatment, then another non-treatment baseline, then another treatment. The approach is valid as long as there is a single post treatment period.
It is intriguing to consider reports of Mr. Harada's course thus far because he had a baseline(downhill), treatment(improved) another quasi baseline in which he went downhill again , a second treatment(improved) again. He demonstrates a single case design success.
Very, very powerful evidence.
The studies by Dr. Pavlov nearly 200 years ago, in which conditioned reflexes were discovered, were done with ONE subject; the results remain valid.
S3 in a non factor. It was necessary from every viewpoint and is nothing more than an excuse for the poor performance by some bagholders on this board. Everyone knows they will need cash and everyone knows they are now in a better position to defend against a hostile takeover.
That's fine xforum, we don't have to agree. In fact it's useful to have different views here. Obviously CUR made their decision not to do a secondary after the NSI-189 Phase 1B data, that window has passed. My thinking was not that they "needed" the cash, but that they could raise cash at a relatively high stock price. The prior secondary was at $1.60, and they'd done one at $0.40 in 2012, so a secondary in the $4's would be the right time to raise some cash - making hay while the sun shines.
The other reason - perhaps even more important - was that CUR had already filed an S3 about a week before the NSI-189 results. Having that hang over the stock, without acting on it swiftly, has likely weighed on the share price. Again, last year they filed an S3 and then did a secondary the following week; the net result was that the share price rose substantially following the secondary. That might not have happened again, but I don't think it's been helpful to have the S3 hanging over CUR's share price like a sword of Damocles. And this was a self-induced situation by CUR management. But what's done is done, we can only look forward from here.
Not only are there people on this board who thought that, there are paid analysts and 'journalists' who stated that publicly. It's a shame that they can actually influence the behavior of this stock.
Interesting. Compare Garr's blog with my (earlier) post in response to Bubbamoo's post "April's Surgery Was 9 Months Ago."
You can tell them till you are blue in the face. The message they send is for the effect they want. There's money to be made with outright lies.
Sentiment: Strong Buy
if anyone here ever really truly believed there would placebo ( fake ) surgeries in ANY phase of this treatments development they are complete and total morons. Just the infection risk is enough to ensure that type of procedure NEVER HAPPENS. I cannot seriously think anyone ever thought that...if so, you should have your drivers license taken because your too stupid to be on the road....if you thought that, don't say anything, just go to mcdonalds and spend the rest of your days playing in the kiddie balls and slides....geeesh are there really people that stupid out there????
Much like i disagreed with you regarding upside when we were trading @ $4.50 post 189 results, I have to disagree with you again here. Why should they have done a secondary in the $4 range? Their cash position is sufficient to last well beyond 566 ALS final results as well as filing for BTD. Which, if they believe in the ALS results as strongly as they have been suggesting, then should also believe in BTD being granted. This alone should price us at +$6 with a possibility of +$8, at which time a secondary would be much more conducive.
I have said all along, they have a very specific price in mind for the secondary (AKA ~$6/share) and have no reason to do so sooner given their current cash position.
Thank You for "Just google "Neuralstem Article Hits Front Page Of The Wall Street Journal" and it comes up for free - lol"
Sentiment: Strong Buy
It mentions Garr and he states that patients that blog and are not feeling well may influence other patients not to participate. Nothing of importance here. IMO